Polo-like kinase inhibitors increase AAV production by halting cell cycle progression
Posted: 3 February 2025Recombinant adeno-associated viruses (rAAVs) are commonly used in gene therapy for preclinical research and therapeutic applications. Despite the clinical efficacy of rAAVs, their manufacturing involves challenges in productivity and quality, leading to limited availability.
Mandegar and colleagues used high-throughput screening to identify cell cycle modulators that enhance AAV production. They found that PLK1 inhibitors significantly increased AAV yields across various conditions by halting the cell cycle. These findings offer potential solutions for improving AAV production to meet high demands with cost-effective manufacturing strategies.
In this study, the team aimed to identify compounds that increase the capacity of cells to produce AAV9 with a high-throughput small-molecule screening strategy. With the Arrayed Targeted Library for AAV Screening platform, we screened a library of 3,300 small molecules and identified several targets, including cell cycle modulators, G protein-coupled receptor modulators, histone deacetylate inhibitors, Janus kinase inhibitors, and metabolic modulators. Most notably, we identified polo-like kinase isoform 1 (PLK1) inhibitors as enhancers of AAV production. Inhibiting PLK1 with HMN-214 increased AAV production, which was largely consistent across HEK293 cell lines, vector payloads, and capsid serotypes. Using cell cycle and RNA-sequencing analysis, we showed that PLK1 inhibition halts cells in the G2/M phase and blocks their exit from the M to G1 phase. These findings support that inhibiting PLK1 may enhance AAV production and could be used to develop more cost-effective methods to manufacture AAV for gene therapies.
To learn more about this study, please do not hesitate and get in touch with business@ascend-adv.com.
The article will appear in Molecular Therapy Journal 33, Issue 1, to be published on 13th March 2025.